Market Value: Rocket Pharmaceuticals Inc (RCKT)

Rocket Pharmaceuticals develops innovative drugs to combat hereditary pathologies. This chart on GURU.Markets confirms the status of a company that attracts top biologists through an ethical culture and stock options, with a market capitalization of 0.27. Elite personnel are motivated by generous bonuses for success in treating children. The market is currently awaiting the filing of registration applications for key cardiology products, and launch costs are already priced in.

RCKT (rocketpharma.com) Market Value history from 07/04/2022 to 11/12/2026

Rocket Corp - analytical breakdowns and key metrics (RCKT)

- current price and projected stock value:

Stock Price Rocket Pharmaceuticals, Inc.|RCKT - Consensus Target

- company stock exchange capitalization indicators:

Market Value Rocket Corp|RCKT - Enterprise Value

- book value of equity indicators:

Accounting Value per Share Rocket Pharmaceuticals|RCKT - Total Net Assets|Market Capitalization to Book Value Ratio rocketpharma.com|RCKT - Total Business Assets

- issuer credit burden and liquidity indicators:

- net income and valuation multiples indicators:

RCKT - Net Income|Expected Profit Rocket Pharmaceuticals|RCKT - P/E Multiple|Forward P/E Multiple Rocket Pharmaceuticals Inc|RCKT - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Rocket Corp|RCKT - Company profit before taxes, interest and amortization|Net earnings per share for the last 12 months Rocket Pharmaceuticals|RCKT - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months rocketpharma.com|RCKT - Earnings per share trend in current year|Earnings growth forecast for next year Rocket Pharmaceuticals

Fundamental company analysis:RCKT (Rocket Pharmaceuticals, Inc.)

Market capitalization reflects the aggregate value of all shares, determining the current scale of the business through daily market quotes. By analyzing the issuer's value on the exchange, an investor identifies consolidation phases and trend reversal points. For Rocket Pharmaceuticals (RCKT), this metric confirms the capitalization of its innovative potential. The independence of its developments from macroeconomic cycles stabilizes the valuation trend. Such resilience makes the asset a reliable defensive tool.

Key competitors